Evaluating Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures

Evaluating Transcutaneous Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures: a Randomized Pilot Study Using Catscan Volumetry

The primary objective of this study is to compare the volume of injected ciment (polymethyl methacrylate) between a group of patients treated with vertebroplasty and a group of patients treated via kyphoplasty. Secondary evaluation will compare the restoration of vertebral height, volume and cyphotic angle between the two techniques, as well as extravation of ciment and functional and quality of life aspects related to these techniques.

Study Overview

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 3 months of follow-up
  • Fracture type according to Magerl Classification (1994) must be one of the following: A1, A2.1, A3.1, A3.2
  • Cyphose of >10°
  • Spinal pain
  • Vertebral fracture < 3 weeks old located between D5 and L5
  • If fragments in the canal, they must protrude less than 40%
  • Absence of other lesions, including cancer

Exclusion Criteria:

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • Patient cannot read French
  • Patient is pregnant or breast feeding
  • Patient has a fracture on an adjacent vertebra
  • Patient has a contra-indication for a treatment used in this study
  • ASA class IV or V
  • Patient has a neurological deficit
  • Previous spinal surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Kyphoplasty
Patients randomized to this arm will be treated via balloon kyphoplasty.
Patients will be treated via a balloon kyphoplasty surgical procedure
Active Comparator: Vertebroplasty
Patients randomized to this arm will be treated via vertebroplasty.
Patients will be treated via a transcutaneous vertebroplasty procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The volume (cm^3) of injected ciment
Time Frame: Baseline (Day 0)
The volume of injected ciment is measured by catscan extrapolated data.
Baseline (Day 0)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recovery of vertebral volume (%)
Time Frame: Day 1 to Day 7
Recovery of vertebral volume relative to theoretical volume based on neighboring vertebra.
Day 1 to Day 7
Change from baseline of the cyphotic angle (°)
Time Frame: Days 1 to 7
The number of degrees of change in the cyphotic angle of the corrected vertebra relative to baseline measurement (°)
Days 1 to 7
Change from baseline of the cyphotic angle (°)
Time Frame: 1 month
The number of degrees of change in the cyphotic angle of the corrected vertebra relative to baseline measurement (°)
1 month
Change from baseline of the cyphotic angle (°)
Time Frame: 3 months
The number of degrees of change in the cyphotic angle of the corrected vertebra relative to baseline measurement (°)
3 months
Change from baseline in vertebral height (mm)
Time Frame: Days 1 to 7
Change in vertebra height (mm) before and after surgery
Days 1 to 7
Change from baseline in vertebral height (mm)
Time Frame: 1 month
Change in vertebra height (mm) before and after surgery
1 month
Change from baseline in vertebral height (mm)
Time Frame: 3 months
Change in vertebra height (mm) before and after surgery
3 months
Volume of ciment leakage (cm^3)
Time Frame: Day 1
The volume of ciment leakage will be determined according to catscan data.
Day 1
Change in Visual Analog Scale (0 to 10) for pain before and after surgery
Time Frame: Day 0 (post-op)
Brute change in Visual Analog Scale (0 to 10) for pain before and after surgery
Day 0 (post-op)
Change in Visual Analog Scale (0 to 10) for pain before and after surgery
Time Frame: 1 month
Brute change in Visual Analog Scale (0 to 10) for pain before and after surgery
1 month
Change in Visual Analog Scale (0 to 10) for pain before and after surgery
Time Frame: 3 months
Brute change in Visual Analog Scale (0 to 10) for pain before and after surgery
3 months
% Change in Visual Analog Scale (0 to 10) for pain before and after surgery
Time Frame: Day 0 (post-op)
The percentage change (%) in Visual Analog Scale (0 to 10) for pain before and after surgery
Day 0 (post-op)
% Change in Visual Analog Scale (0 to 10) for pain before and after surgery
Time Frame: 1 month
The percentage change (%) in Visual Analog Scale (0 to 10) for pain before and after surgery
1 month
% Change in Visual Analog Scale (0 to 10) for pain before and after surgery
Time Frame: 3 months
The percentage change (%) in Visual Analog Scale (0 to 10) for pain before and after surgery
3 months
The change in the ODI score before and after surgery
Time Frame: 3 months
The change in the Oswestry Disability Index before and after surgery
3 months
The % change in the ODI score before and after surgery
Time Frame: 3 months
The percentage change (%) in the Oswestry Disability Index before and after surgery
3 months
Change in SF-36 quality of life score before and after surgery
Time Frame: 1 month
Change in SF-36 quality of life score before and after surgery
1 month
Change in SF-36 quality of life score before and after surgery
Time Frame: 3 months
Change in SF-36 quality of life score before and after surgery
3 months
The % change in SF-36 quality of life score before and after surgery
Time Frame: 1 month
Percentage change (%) in SF-36 quality of life score before and after surgery
1 month
The % change in SF-36 quality of life score before and after surgery
Time Frame: 3 months
Percentage change (%) in SF-36 quality of life score before and after surgery
3 months
Change in FABQ score before and after surgery
Time Frame: 1 month
Change in the Fear-Avoidance Beliefs Questionnaire score before and after surgery
1 month
Change in FABQ score before and after surgery
Time Frame: 3 months
Change in the Fear-Avoidance Beliefs Questionnaire score before and after surgery
3 months
% Change in FABQ score before and after surgery
Time Frame: 1 month
Percentage change (%) in the Fear-Avoidance Beliefs Questionnaire score before and after surgery
1 month
% Change in FABQ score before and after surgery
Time Frame: 3 months
Percentage change (%) in the Fear-Avoidance Beliefs Questionnaire score before and after surgery
3 months
Change in DPQ score before and after surgery
Time Frame: 1 month
Change in the Dallas Pain Questionnaire score before and after surgery
1 month
Change in DPQ score before and after surgery
Time Frame: 3 months
Change in the Dallas Pain Questionnaire score before and after surgery
3 months
% Change in DPQ score before and after surgery
Time Frame: 3 months
Percentage change (%) in the Dallas Pain Questionnaire score before and after surgery
3 months
% Change in DPQ score before and after surgery
Time Frame: 1 month
Percentage change (%) in the Dallas Pain Questionnaire score before and after surgery
1 month
Duration of surgery (minutes)
Time Frame: Day 0 (day of surgery)
Length of operative time (minutes)
Day 0 (day of surgery)
Presence / absence of per-operative complications
Time Frame: Day 0 (day of surgery)
Presence / absence of per-operative complications
Day 0 (day of surgery)
Presence / absence of post-operative complications
Time Frame: 1 month
Presence / absence of post-operative complications
1 month
Presence / absence of post-operative complications
Time Frame: 3 months
Presence / absence of post-operative complications
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pascal Kouyoumdjian, MD, Centre Hospitalier Universitaire de Nîmes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Anticipated)

May 1, 2016

Study Completion (Anticipated)

August 1, 2016

Study Registration Dates

First Submitted

July 25, 2011

First Submitted That Met QC Criteria

July 25, 2011

First Posted (Estimate)

July 26, 2011

Study Record Updates

Last Update Posted (Estimate)

March 25, 2015

Last Update Submitted That Met QC Criteria

March 24, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • LOCAL/2011/PK-04

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vertebral Body Compression Fractures

Clinical Trials on Kyphoplasty

3
Subscribe